|
21 Jul 2019 |
Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX® (daratumumab)
|
|
19 Jul 2019 |
EMA Accepts Samsung Bioepis’ MAA for SB8 Bevacizumab Biosimilar Candidate
|
|
19 Jul 2019 |
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
|
|
18 Jul 2019 |
MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
|
|
17 Jul 2019 |
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
|
|
17 Jul 2019 |
Orum Therapeutics Announces $30 Million Series B Financing to Advance Cell-Penetrating, Cell-Specific Antibody Technology for Novel Therapeutics
|
|
16 Jul 2019 |
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
|
|
16 Jul 2019 |
Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
|
|
16 Jul 2019 |
Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma
|
|
16 Jul 2019 |
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
|
|
16 Jul 2019 |
SurgiMab Advances SGM-101, a Novel Fluorescent Tumor-specific Antibody, Into Pivotal Phase 3 Clinical Trial to Improve Surgical Outcomes in Colorectal Cancer Patients
|
|
13 Jul 2019 |
Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX® (daratumumab) Subcutaneous Formulation
|
|
10 Jul 2019 |
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
|
|
09 Jul 2019 |
FDA Accepts Merck’s Supplemental Biologics License Applications for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule for Melanoma and Multiple Other Indications
|
|
08 Jul 2019 |
Y-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab
|
|
08 Jul 2019 |
Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471
|
|
08 Jul 2019 |
Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab
|
|
08 Jul 2019 |
Concizumab phase 2 data demonstrate its potential as a safe and efficacious subcutaneous prophylaxis treatment for all patients with haemophilia
|
|
07 Jul 2019 |
Positive Data from Completed Phase 1/2a study of BIVV001 Presented at ISTH 2019
|
|
05 Jul 2019 |
GamaMabs Pharma announces presentation of murlentamab phase 2 study results in colorectal cancer at ESMO World Congress on Gastrointestinal Cancer
|
|
04 Jul 2019 |
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
|
|
04 Jul 2019 |
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
|
04 Jul 2019 |
BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application
|
|
03 Jul 2019 |
GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
|
|
02 Jul 2019 |
Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
|
